keyword
MENU ▼
Read by QxMD icon Read
search

Plaque psoriasis

keyword
https://www.readbyqxmd.com/read/29790131/efficacy-and-safety-outcomes-for-originator-tnf-inhibitors-and-biosimilars-in-rheumatoid-arthritis-and-psoriasis-trials-a-systematic-literature-review
#1
REVIEW
Robert J Moots, Cinzia Curiale, Danielle Petersel, Catherine Rolland, Heather Jones, Eduardo Mysler
OBJECTIVE: Regulatory approval of biosimilar versions of originator biotherapeutics requires that new biological products be highly similar to originator products, with no clinically meaningful differences in safety, purity, and potency. In some trials of biosimilars of tumor necrosis factor inhibitors for the treatment of rheumatoid arthritis (RA) and plaque psoriasis (PsO), pre-specified margins for efficacy and safety have been met, but differences in treatment responses between pivotal originator trials and biosimilar trials have been noted...
May 22, 2018: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29788767/limitations-of-current-monoclonal-antibodies-for-plaque-type-psoriasis-and-an-outlook-for-the-future
#2
Annunziata Raimondo, Anna Balato, Matteo Megna, Nicola Balato
No abstract text is available yet for this article.
May 23, 2018: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/29785820/allocation-of-biologics-health-economics-and-clinical-decision-making-in-plaque-psoriasis
#3
EDITORIAL
N Bray, P Wolf
No abstract text is available yet for this article.
May 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29785237/early-onset-of-clinical-improvement-with-ixekizumab-in-a-randomized-open-label-study-of-patients-with-moderate-to-severe-plaque-psoriasis
#4
Saakshi Khattri, Orin Goldblum, Kathleen Solotkin, Yasmin Amir, Michelle S Min, Terri Ridenour, Fan Emily Yang, Mark Lebwohl
Objective: The purpose of this study was to evaluate the speed of onset of clinical response to ixekizumab (IXE) and assess the progression of visible improvement in patients with moderate-to-severe plaque psoriasis. Design: This was an interventional, randomized, open-label, Phase IIIb clinical trial. Setting: This was a single center study at the Mount Sinai School of Medicine. Participants: Twelve patients were randomized at a ratio of 1:1 to receive 80mg of ixekizumab every two (IXE Q2W) or four (IXE Q4W) weeks following a starting dose of 160mg of ixekizumab...
May 2018: Journal of Clinical and Aesthetic Dermatology
https://www.readbyqxmd.com/read/29782642/tofacitinib-in-patients-with-moderate-to-severe-chronic-plaque-psoriasis-long-term-safety-and-efficacy-in-an-open-label-extension-study
#5
F Valenzuela, N J Korman, R Bissonnette, N Bakos, T-F Tsai, M K Harper, W C Ports, H Tan, A Tallman, H Valdez, A C Gardner
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor. Final safety and efficacy data from an open-label extension study of tofacitinib in psoriasis are reported. OBJECTIVE: To evaluate the long-term safety and durability of efficacy of tofacitinib in adults with moderate to severe chronic plaque psoriasis. METHODS: Eligible patients who completed qualifying Phase 2/3 tofacitinib studies received tofacitinib 10 mg twice daily (BID) until Month 3; subsequently, the dose could be adjusted by investigators to either 5 or 10 mg BID...
May 21, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29782303/clindamycin-induced-maculopapular-exanthema-with-preferential-involvement-of-striae-distensae-a-koebner-phenomenon
#6
Benigno Monteagudo, Miguel Cabanillas, Pilar Iriarte, Aquilina Ramírez-Santos, Elvira León-Muinos, Daniel González-Vilas, Óscar Suárez-Amor
Clindamycin is a lincomycin-derived antibiotic useful for the treatment of anaerobic and Gram-positive aerobic bacterial infections. Cutaneous adverse reactions are usually maculopapular exanthemas, although hypersensitivity syndrome, acute generalized exanthematous pustulosis, and Stevens-Johnson syndrome have also been reported (1). We report the case of a patient with a maculopapular rash triggered by clindamycin who developed cutaneous lesions on striae distensae (SD). A 47-year-old woman was referred to our clinic for pruritic cutaneous lesions which had started 6 days earlier...
April 2018: Acta Dermatovenerologica Croatica: ADC
https://www.readbyqxmd.com/read/29776016/psoriasis-area-and-severity-index-pasi-response-in-moderate-severe-psoriatic-patients-switched-to-adalimumab-results-from-the-oppsa-study
#7
M Talamonti, M Galluzzo, N Bernardini, G Caldarola, S Persechino, F Cantoresi, C G Egan, C Potenza, K Peris, L Bianchi
BACKGROUND: Few studies have compared the efficacy of switching to adalimumab in the real-life setting in plaque psoriasis patients. OBJECTIVE: To evaluate the effect of adalimumab in psoriasis patients previously treated with other biologics. METHODS: In this multicentre study, psoriasis patients (N=262) treated with an anti-TNF alpha agent, ustekinumab or naïve to biologics then switched to adalimumab were included. Disease severity was assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 3, 6, 12, 24 and 36 months...
May 18, 2018: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/29773695/automated-computer-guided-pasi-measurements-by-digital-image-analysis-versus-conventional-physicians-pasi-calculations-study-protocol-for-a-comparative-single-centre-observational-study
#8
Christine Fink, Lorenz Uhlmann, Christina Klose, Holger A Haenssle
INTRODUCTION: Reliable and accurate assessment of severity in psoriasis is very important in order to meet indication criteria for initiation of systemic treatment or to evaluate treatment efficacy. The most acknowledged tool for measuring the extent of psoriatic skin changes is the Psoriasis Area and Severity Index (PASI). However, the calculation of PASI can be tedious and subjective and high intraobserver and interobserver variability is an important concern. Therefore, there is a great need for a standardised and objective method that guarantees a reproducible PASI calculation...
May 17, 2018: BMJ Open
https://www.readbyqxmd.com/read/29771632/immunohistochemical-expression-hif1%C3%AE-in-chronic-plaque-psoriasis-an-association-with-angiogenesis-and-proliferation
#9
Asmaa Gaber Abdou, Azza G A Farag, Moustafa Hammam, Doha Maher Taie, Reem Ahmed Abdelaziz
Psoriasis is characterized by excessive cell proliferation, angiogenesis, and regions of hypoxia. Hypoxia stimulates production of hypoxia inducible factors (HIFs) such as HIF1α. The aim of the present study is to investigate the possible role of HIF1α in pathogenesis of psoriasis and to correlate its expression with angiogenesis and proliferation in involved and uninvolved skin in patients with plaque psoriasis using CD34 and Ki-67. The current study was performed on 40 skin specimens of patients presented with chronic plaque psoriasis both involved and uninvolved together with 40 specimens from age- and sex-matched healthy volunteers as a control group...
May 17, 2018: Journal of Immunoassay & Immunochemistry
https://www.readbyqxmd.com/read/29760617/roc-analysis-of-selected-matrix-metalloproteinases-mmps-and-tissue-inhibitors-of-metalloproteinases-timps-in-psoriatic-patients
#10
Edyta K Glazewska, Marek Niczyporuk, Slawomir Lawicki, Maciej Szmitkowski, Monika Zajkowska, Magdalena Donejko, Andrzej Przylipiak
Introduction: Psoriasis is a common, chronic inflammatory disease characterised by typical scaly skin lesions. The role of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the pathogenesis and development of this condition have been repeatedly emphasised in available literature. Aim: ROC analysis of selected MMPs (MMP-2, MMP-3, MMP-9, MMP-12, TIMP-2) and TIMPs (TIMP-2, TIMP-3) in psoriasis patients. The area under the ROC curve (AUC) indicates the clinical usefulness of a biomarker and its diagnostic power...
April 2018: Postȩpy Dermatologii i Alergologii
https://www.readbyqxmd.com/read/29757042/comparison-of-napsi-and-n-nail-for-evaluation-of-fingernail-psoriasis-in-patients-with-moderate-to-severe-plaque-psoriasis-treated-using-ustekinumab
#11
Bo Ri Kim, Seungkeol Yang, Chong Won Choi, Sang Woong Youn
OBJECTIVE: We sought to determine which psoriatic nail features more effectively respond to ustekinumab treatment and evaluate which between the Nail Psoriasis Severity Index (NAPSI) and the Nijmegen-Nail psoriasis Activity Index tooL (N-NAIL) better reflects the clinical improvement of nail psoriasis. METHODS: Thirty patients with moderate-to-severe plaque psoriasis were prospectively enrolled; the patients were treated with ustekinumab for 52 weeks. A single investigator evaluated the condition using the NAPSI and the N-NAIL with serial fingernail photographs...
May 14, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29752706/tildrakizumab-first-global-approval
#12
Anthony Markham
Merck & Company Inc. have developed tildrakizumab (tildrakizumab-asmn; Ilumya™), a high-affinity, humanised IgG1 κ monoclonal antibody that specifically targets interleukin-23 p19, as a treatment for chronic plaque psoriasis. The drug was recently approved for marketing by the US FDA based on positive results from the phase III reSURFACE clinical trial programme in patients with chronic plaque psoriasis. This article summarizes the milestones in the development of tildrakizumab leading to this first approval for the treatment of adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy...
May 11, 2018: Drugs
https://www.readbyqxmd.com/read/29751001/ixekizumab-pharmacokinetics-anti-drug-antibodies-and-efficacy-through-60-weeks-of-treatment-of-moderate-to-severe-plaque-psoriasis
#13
Kristian Reich, Kimberley Jackson, Susan Ball, Sandra Garces, Lisa Kerr, Laiyi Chua, Talia M Muram, Andrew Blauvelt
Ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A, is efficacious for moderate-to-severe plaque psoriasis. We examined relationships between serum ixekizumab concentrations, treatment-emergent anti-drug antibodies (TE-ADA), and efficacy during 60 weeks of treatment in a randomized, controlled, phase 3 study. Steady-state ixekizumab serum trough concentrations were rapidly achieved and associated with high clinical responses at week 12 with a starting dose of 160 mg followed by 80 mg every 2 weeks...
May 8, 2018: Journal of Investigative Dermatology
https://www.readbyqxmd.com/read/29749363/a-non-inferiority-randomized-controlled-clinical-trial-comparing-unani-formulation-psoralen-plus-ultraviolet-a-sol-in-chronic-plaque-psoriasis
#14
Neena Khanna, Tamanna Nazli, Khalid Mahmud Siddiqui, Mani Kalaivani
Background & objectives: Though Unani medications have been used for centuries to treat psoriasis, there is paucity of published studies which have systematically evaluated their efficacy and safety. This study was conducted to establish non-inferiority of Unani medications (oral UNIM-401 and topical UNIM-403) vs psoralen plus ultraviolet A (PUVA) sol in treatment of moderate-severe chronic plaque psoriasis (CPP) in achieving psoriasis area severity index (PASI) 75 at 12 wk and to estimate proportion of patients who relapsed in follow up period of 12 weeks, after having achieved PASI 50...
January 2018: Indian Journal of Medical Research
https://www.readbyqxmd.com/read/29747232/efficacy-and-safety-of-ixekizumab-in-a-randomized-double-blinded-placebo-controlled-phase-3b-study-of-patients-with-moderate-to-severe-genital-psoriasis
#15
C Ryan, A Menter, L Guenther, A Blauvelt, R Bissonnette, K Meeuwis, J Sullivan, J C Cather, G Yosipovitch, A B Gottlieb, J F Merola, K Callis Duffin, S Fretzin, O O Osuntokun, R Burge, A N Naegeli, F E Yang, C-Y Lin, K Todd, A Potts Bleakman
BACKGROUND: Genital psoriasis (GenPs) is a common, debilitating, and difficult to treat manifestation of plaque psoriasis. However, few controlled, interventional studies of GenPs exist. OBJECTIVE: To determine the efficacy of ixekizumab versus placebo in patients with moderate-to-severe GenPs with BSA≥1%. METHODS: Subjects with moderate-to-severe GenPs (defined as a baseline static Physician's Global Assessment of Genitalia [sPGA-G] score of ≥3) with BSA≥1% were randomized 1:1 to receive placebo (N=74) or the recommended dosing of ixekizumab (N=75)...
May 10, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29746636/emergence-of-inflammatory-bowel-disease-during-treatment-with-secukinumab
#16
María José Fobelo Lozano, Reyes Serrano Giménez, Manuel Castro Fernández
Secukinumab is an anti-IL 17A monoclonal antibody currently licensed for the treatment of plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. However, although inflammatory bowel disease is a disorder with related immune characteristics, secukinumab has not proved to be effective in these diseases. In fact, negative results in a clinical trial designed to assess its efficacy in patients with Crohn disease have been published. On the other hand, the drug fact sheet states that secukinumab should be used with caution in patients with inflammatoy bowel disease...
May 9, 2018: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/29742274/safety-of-tildrakizumab-for-moderate-to-severe-plaque-psoriasis-pooled-analysis-of-three-randomised-controlled-trials
#17
A Blauvelt, K Reich, K A Papp, A B Kimball, M Gooderham, S K Tyring, R Sinclair, D Thaci, Q Li, N Cichanowitz, S Green, C La Rosa
BACKGROUND: Short-term IL-23p19 inhibition by tildrakizumab improves plaque psoriasis and appears well-tolerated. OBJECTIVES: Safety/tolerability were assessed for up to 64 weeks of tildrakizumab therapy using pooled data from 3 randomised controlled trials for moderate-to-severe psoriasis. METHODS: Data pools for the placebo-controlled (up to 16 weeks) and full-trial periods (up to 64 weeks) were analysed (N=2081). RESULTS: In the placebo-controlled period, frequencies of treatment-emergent adverse events (TEAEs; range=47...
May 9, 2018: British Journal of Dermatology
https://www.readbyqxmd.com/read/29740870/asian-consensus-on-assessment-and-management-of-mild-to-moderate-plaque-psoriasis-with-topical-therapy
#18
Shinichi Imafuku, Min Zheng, Yayoi Tada, Xibao Zhang, Colin Theng, Suganthi Thevarajah, Yi Zhao, Hae Jun Song
A working group of dermatologists in Asian countries assessed the current status of psoriatic management in the region to prepare a consensus report on topical treatment in mild to moderate plaque psoriasis. Even though the association of psoriasis with systemic comorbidities is increasingly acknowledged, psoriasis is still lower in health-care priority lists in the region. The psychosocial impact of psoriasis may be greater in Asian countries due to cultural norms and social discrimination. Non-adherence to treatment is also common among Asians...
May 9, 2018: Journal of Dermatology
https://www.readbyqxmd.com/read/29737896/systematic-review-of-anti-drug-antibodies-of-il-17-inhibitors-for-psoriasis
#19
Logan W Thomas, Erica B Lee, Jashin J Wu
Three main biologics target the IL-17 pathway; these include secukinmab, ixekizumab, brodalumab, all of which are approved for treatment of moderate-to-severe plaque psoriasis. We performed a systematic review of the literature to determine if IL-17 inhibitors are prone to developing ADA and how efficacy of treatment is influenced. A total of 14 papers were reviewed. Only one secukinmab trial detected treatment-emergent ADA in 4 out of 996 (0.41%) patients during the 52-week treatment period. Two of these patients (1 on 150-mg retreatment as needed and 1 on 150-mg fixed interval) were found to have neutralizing antibodies, however they were not associated with decreased efficacy...
May 8, 2018: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/29736839/stricturing-and-fistulizing-crohn-s-disease-is-associated-with-anti-tumor-necrosis-factor-induced-psoriasis-in-patients-with-inflammatory-bowel-disease
#20
Adam V Weizman, Robyn Sharma, N M Afzal, Wei Xu, Scott Walsh, Joanne M Stempak, Geoffrey C Nguyen, Ken Croitoru, A Hillary Steinhart, Mark S Silverberg
BACKGROUND: Paradoxical development of psoriasis in patients on anti-TNF agents has been increasingly reported. AIM: The aim was to characterize the prevalence and clinical characteristics of anti-TNF-associated psoriasis in a large cohort of inflammatory bowel disease patients. METHODS: Medical records of patients with Crohn's disease or ulcerative colitis treated with anti-TNF therapy at a single, tertiary IBD center were identified between 2004 and 2016...
May 8, 2018: Digestive Diseases and Sciences
keyword
keyword
82378
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"